Annovis Bio

ANVS

Biotechnology · Healthcare

Price

$1.88

+0.02 (+1.08%)

Market Cap

$37.0M

Exchange

New York Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+169.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.6M (2021) → 20.6M (2025)

Annovis Bio is a small clinical-stage drug company trying to develop treatments for brain diseases like Alzheimer's and Parkinson's. Its main drug candidate is called buntanetap, which is designed to reduce toxic proteins that build up in the brain and damage nerve cells. The company's potential customers are patients and healthcare providers dealing with these serious neurological conditions.

Annovis makes no product revenue right now because its drugs are still being tested in clinical trials. It operates primarily in the United States and is a very small company, funded mainly by selling shares to investors rather than selling products. The company's future depends almost entirely on whether buntanetap succeeds in clinical trials — if the drug fails to show clear benefits in late-stage testing, the company could run out of funding and face serious financial trouble.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-96.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$25M/ year

↑ Rising (+26% vs prior year)

R&D investment increasing — building for the future

Insider Activity

17.0%ownership

Insiders own a meaningful stake in the company

Cash Runway

~5 months

$14M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Annovis Bio has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-576.2%

Weak — -576.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial